全文获取类型
收费全文 | 320篇 |
免费 | 33篇 |
学科分类
医药卫生 | 353篇 |
出版年
2023年 | 1篇 |
2020年 | 3篇 |
2018年 | 1篇 |
2017年 | 4篇 |
2016年 | 2篇 |
2015年 | 1篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 7篇 |
2011年 | 5篇 |
2010年 | 3篇 |
2009年 | 4篇 |
2008年 | 15篇 |
2007年 | 10篇 |
2006年 | 20篇 |
2005年 | 22篇 |
2004年 | 16篇 |
2003年 | 12篇 |
2002年 | 17篇 |
2001年 | 17篇 |
2000年 | 30篇 |
1999年 | 21篇 |
1998年 | 6篇 |
1997年 | 13篇 |
1996年 | 13篇 |
1995年 | 3篇 |
1994年 | 7篇 |
1993年 | 12篇 |
1992年 | 3篇 |
1991年 | 10篇 |
1990年 | 16篇 |
1989年 | 12篇 |
1988年 | 6篇 |
1987年 | 7篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1966年 | 2篇 |
排序方式: 共有353条查询结果,搜索用时 31 毫秒
1.
Eradication of established tumors by CD8+ T cell adoptive immunotherapy 总被引:14,自引:0,他引:14
Hanson HL Donermeyer DL Ikeda H White JM Shankaran V Old LJ Shiku H Schreiber RD Allen PM 《Immunity》2000,13(2):265-276
We generated the DUC18 T cell receptor transgenic mouse expressing an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144). DUC18 mice were capable of specifically eliminating lethal CMS5 tumor challenges, and transfer of DUC18 splenocytes to naive nontransgenic recipients conferred protection from subsequent and established CMS5 tumor burdens. Eradication of established tumor burdens by adoptive transfer of DUC18 splenocytes was dose and time dependent. Transferred tumor-specific T cells remained functional in vivo and capable of rejecting small tumors even in the presence of large, established tumor burdens. These findings highlight the kinetic battle between tumor growth and the production of a tumor-specific response and have critical implications for effective adoptive immunotherapy. 相似文献
2.
3.
Ichihashi T Yamaguchi H Furukawa K Shiku H Naoe T Ohno R 《International journal of oncology》1993,2(4):483-491
We analyzed the genetic origins of anti-GD3 antibodies by comparing nucleotide sequences of the variable regions from the human monoclonal antibody (mAb), 27-26 (mu, k), established from a patient with leukemia, and another human anti-GD3 mAb, HJM-1 (mu, lambda) derived from a patient with melanoma. The variable regions of 27-26 and HJM-1 were remarkably similar to the germ-line genes. The mAb 27-26 was thought to be derived from germ-line repertoire expanded throughout our experiment. HJM-1 was derived from lymphocytes stimulated by GD3 abundantly expressed on melanoma cells. 相似文献
4.
Kobayashi T Clodi K Yang Y Ruan S Shiku H Andreeff M Shay J Zhang W 《International journal of oncology》1997,11(1):13-17
In most normal somatic cells the telomeres of human chromosomes shorten with each cell division because of low expression or lack of telomerase activity. Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is reactivated or upregulated in tumor cells and maintains the stability of telomere length. We previously showed that treatment of HL60 leukemia cells with differentiation-inducing agents resulted in inhibition of telomerase activity. In the present study, we found that the decrease in telomerase activity did not temporally correlate with the expression of a differentiation marker, CD11b, on the cell surface. Mixing of protein extracts from telomerase-negative differentiated HL60 cells with those from parental HL60 cells did not result in inhibition of telomerase activity, suggesting that a diffusible cellular telomerase inhibitor was not produced in the differentiated cells. However, a decrease in telomerase activity correlated with a selective decrease of telomerase RNA expression, a decrease in the levels of total cellular RNA, and an increase in cells at G(0) phase. 相似文献
5.
6.
7.
Mahmud N Katayama N Itoh R Ohishi K Masuya M Minami N Shiku H 《International journal of oncology》1996,8(3):453-459
We examined the effects of granulocyte colony-stimulating factor (G-CSF) on cell-cycling of hematopoietic progenitors in serum-free methylcellulose clonal cultures. Serial observations of the cultures showed hastening of growth of colonies by G-CSF, as determined by evaluating the time for individual colonies of 20 cells to reach 40 cells. G-CSF did not affect the incidence of proliferating cells in each developing colony. Cell-cycle analysis revealed that addition of G-CSF to cultures led to a decrease in the percentage of cells in the G1 phase of the cell-cycle, thereby indicating that G-CSF can modulate the cell-cycle of hematopoietic progenitors mainly by shortening the period of the G1 phase. Tumor necrosis factor alpha (TNF alpha) exerted opposite effects on cell-cycling of hematopoietic progenitors to those seen with G-CSF. G-CSF abolished the inhibitory effects of TNF alpha on the cell-cycling of hematopoietic progenitors. These observations indicate positive and negative regulatory roles of C-CSF and TNF alpha, respectively, and their interactions in the regulation of cell-cycling of hematopoietic progenitors. 相似文献
8.
Joh T Yamada Y Seto M Nakamura S Ohmoto Y Kamihira S Tomonaga M Shiku H 《International journal of oncology》1996,9(4):619-624
Stromal cells isolated from lymph nodes of adult T-cell leukemia/lymphoma (ATL) patients were cultured. Such lymph node stromal cells (LNSC) could be maintained for more than one year, whereas LNSC from other lymphoproliferative disorders ceased to proliferate within months. The rate of human T lymphotropic virus type I (HTLV-I) integration in these LNSC was examined by nested polymerase chain reaction (PCR) and estimated to be about 1 genome per 100 cells. These LNSC showed the same combination of cytokine production irrespective of the patient origin, granulocyte-macrophage (GM)-CSF, G-CSF, interleukin (IL)-1 beta, IL-6, interferon (IFN)-gamma and IL-8, being positive but not M-CSF, IL-1 alpha, IFN-alpha, tumor necrosis factor (TNF)-alpha, IL-2, LD78 and the IL-1 receptor antagonist (IL-1ra). The results show that LNSC from ATL patients have pronounced proliferation activity and constitutively secrete various cytokines. They therefore provide useful models for studying the microenvironment of lymph nodes in vitro, and especially the growth mechanism of ATL cells. 相似文献
9.
T. Goi A. Yamaguchi G. Nakagawara T. Urano H. Shiku K. Furukawa 《British journal of cancer》1998,77(3):466-471
Using a bacterial fusion protein, a deleted colorectal carcinoma (DCC)-specific monoclonal antibody (MAb) 127-22 was established. Although MAb 127-22 reacted with almost all normal tissues, it did not react or only weakly reacted with many cancer cell lines, including colonic cancer lines, in flow cytometry. In Western immunoblots, the MAb reacted with a single 190-kDa molecule in a myeloma line Ara-10 extract. This component was scarcely detected in colonic cancer cell lines. Immunoblots of samples from 25 pairs of colonic cancers and adjacent normal tissues and from five adenoma tissues revealed that all normal colonic and adenoma tissues significantly expressed the DCC protein, whereas colonic cancer tissues showed poor expression. These results indicate not only deletion of and lowered mRNA expression of the DCC gene, but also marked reduction of DCC protein occurred in colonic cancer tissues. In addition, colonic cancer patients with liver metastasis expressed significantly lower levels of DCC than those without, suggesting the prognostic value of DCC expression. 相似文献
10.
High plasma fibrinogen level is associated with poor clinical outcome in DIC patients 总被引:1,自引:0,他引:1
Wada H Mori Y Okabayashi K Gabazza EC Kushiya F Watanabe M Nishikawa M Shiku H Nobori T 《American journal of hematology》2003,72(1):1-7
We measured the plasma level of fibrinogen in 560 patients with disseminated intravascular coagulation (DIC) and evaluated its relationship with outcome and with other hemostatic markers. Forty-seven percent of patients had >200 mg/dL of plasma fibrinogen and 24% had <100 mg/dl of plasma fibrinogen, suggesting that plasma fibrinogen level is not a sensitive marker for DIC. In our analysis of outcome and plasma fibrinogen levels, the rate of death was high in leukemia/lymphoma patients with high fibrinogen concentration, but no significant difference in outcome was observed in relation to plasma fibrinogen concentration in non-leukemia/lymphoma patients with DIC. Among patients with leukemia/lymphoma, the frequency of organ failure was markedly high in patients with high plasma levels of fibrinogen. Among patients without leukemia/lymphoma, the frequency of organ failure increased concomitantly with the increase in plasma fibrinogen levels. The international normalized ratio was significantly increased in leukemia/lymphoma patients with low fibrinogen. FDP levels were slightly increased in patients with low fibrinogen. Platelet count was significantly low in patients without leukemia/lymphoma with high fibrinogen. DIC score increased concomitantly with the reduction in plasma fibrinogen levels. Plasma levels of thrombomodulin and tissue factor were significantly high in patients with high fibrinogen levels. Plasma levels of antiplasmin and plasminogen were significantly decreased in patients with low fibrinogen. Plasma levels of plasmin plasmin-inhibitor complex and tissue type plasminogen activator/plasminogen activator inhibitor-1 complex (PAI-I) were significantly higher in patients with low fibrinogen than in those with high fibrinogen. Plasma levels of PAI-I and IL-6 were significantly higher in patients with high fibrinogen than in those with low fibrinogen. Patients with high fibrinogen levels showed less activation of secondary fibrinolysis, which might explain the occurrence of organ failure and poor outcome. 相似文献